LDS/Medical Tests/Antibody Identification, Erythrocytes

Antibody Identification, Erythrocytes

Antibody identification is important not just to assure compatible blood can be made available for transfusion but also for treating clinically significant anemia of any etiology and preventing and treating some fetal complications during pregnancy. Immunization to red cell antigens through pregnancy, prior transfusion, bone marrow or solid organ transplantation, needle sharing or injection of immunogenic material may result in a patient developing antibodies directed toward an antigen the individual lacks on his own red blood cells. Such antibodies are termed alloantibodies (also called unexpected antibodies). Autoantibodies (antibodies formed by a patient without exposure to another person’s blood) are directed toward an antigen that is present on the patient’s own red blood cells. These may be formed as the result of a defect in the patient’s humoral immune response such as with hematologic malignancies or for unknown reasons. In addition, antibodies directed against a patient’s own red blood cells may be detected in patients taking certain drugs (e.g., dopamine, cephalosporins) or who have had certain infections (e.g., mycoplasma, mononucleosis, CMV). Antibody identification is critical to guiding proper therapy in the obstetrical patient population (namely, Rh immune globulin, periumbilical cord blood sampling) to prevent or treat hemolytic disease of the fetus and newborn and provide appropriately compatible blood when needed.

The first step in antibody identification is to review the patient’s history. Any clinically significant antibody previously identified, even if not detectable in the current specimen must be honored for the purposes of transfusion. Unexpected red cell antibodies may be detected in a routine pretransfusion antibody screen. When the antibody screen is positive, testing the patient’s serum or plasma against a panel of red blood cells of known phenotype is performed to evaluate the pattern of reactivity and determine alloantibody specificity. Additional techniques may be needed to enhance or suppress antibody reactivity to fully evaluate the antibody (ies) (i.e. LISS, PEG, selected cells, enzyme treatment). Once identified, the antibody (ies) must be evaluated for clinical significance and appropriate antigen-negative blood selected for transfusion if necessary. Once clinically significant antibody (ies) is/are identified, donor blood that is negative for the corresponding antigen should be used for transfusion. A full crossmatch is required and only blood that is crossmatch compatible should be issued.

There are many clinically significant antibodies that can cause a hemolytic reaction, whether acute or delayed. However, some might not be clinically significant (not cause a hemolytic reaction). All clinically significant antibodies should be documented and taken into account with each transfusion and/or pregnancy. An alloantibody is not considered clinically significant if it is not likely to cause a transfusion reaction or hemolytic disease of the newborn. It is not necessary to find antigen negative (crossmatch compatible) blood if the antibody identified is not clinically significant. However, a record of the antibody must be kept regardless of clinical significance, and the presence of all clinically significant antibodies must still be ruled out.

Finding antigen negative (crossmatch compatible) blood may be relatively easy, or extremely difficult, depending on the number and type of antibodies present.

Infants less than six months old generally do not produce red cell antibodies. Clinically significant antibodies detected in an infant are most likely passively acquired from the mother and corresponding antigens must be avoided.

An alloantibody is considered clinically significant if it is frequently associated with hemolytic disease of the fetus and the newborn (HDFN), hemolytic transfusion reactions or a notable decrease in transfused red cell survival.

Examples of commonly encountered clinically significant antibodies are: Rh group (D, C, E, c, e), Kell (K, k, Ku), Duffy (Fya, Fyb, Fy3), Kidd (Jka, Jkb, Jk3), Diego (Dia, Dib, Wra), MNS (S, s), A1

Less Clinically Significant, but still can cause reaction: MNS (U, Vw, Mur),Vel, Ge, Hy, Yta

Usually not clinically significant: Lutheran (Lua, Lub), Lewis (Lea, Leb), MNS (M, N), P1, Clinically Not Significant: JMH, Bg, Csa, Xga

  • Antibody identification to prevent Hemolytic Disease of the Fetus and Newborn (HDFN).
  • To confirm the presence and determine the cause of HDFN.
  • Before RBC transfusions as part of pretransfusion testing, a "type and screen" or "type and crossmatch."
  • In the investigation of a suspected transfusion reaction.
  • To investigate immune hemolytic anemia and guide treatment.
  • Blood donor screening and identification to prevent transfusion reaction in recipients.

Any antibody detected that can cause hemolytic anemia is considered clinically significant.

  • Examples of commonly encountered clinically significant antibodies are: Rh group (D, C, E, c, e), Kell (K, k, Ku), Duffy (Fya, Fyb, Fy3), Kidd (Jka, Jkb, Jk3), Diego (Dia, Dib, Wra), MNS (S, s), A1
  • Less Clinically Significant, but still can cause reaction: MNS (U, Vw, Mur),Vel, Ge, Hy, Yta
  • Usually not clinically significant: Lutheran (Lua, Lub), Lewis (Lea, Leb), MNS (M, N), P1,
  • Clinically Not Significant: JMH, Bg, Csa, Xga

Antibody not detected (Negative)

Manual tube method with and without saline, LISS, PEG, albumin enhancement (antigen antibody agglutination method), the gel method (antigen antibody agglutination method), solid phase red cell adherence (SPRCA).

Red top tube, lavender top tube (EDTA tube)

Less than 72 hours old is preferred. No serum separator tubes. Sample should be stored at 2-8 C if testing cannot be performed immediately.

Stability

  • Ambient: 72 hours
  • Refrigerated: 5-7 days
Antigen screen, direct antiglobulin test (DAT), antibody titer, antibody subtype (IgG, IgA or IgM) red blood cell antigen genotyping, thermal amplitude, monocyte-monolayer antibody testing, antibody absorption studies, antibody elution studies, drug induced antibody testing, enzyme treatment, Donath-Landsteiner test.
1-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Transfusion. 2004 Sep. 44(9):1273-81. [PMID: 15318848]
  • Obstet Gynecol Surv. 1989.44(9): 637-41. [PMID: 2771305]
  • Daniels Geoff. Human Blood Groups, 3rd edition. Wiley-Blackwell, 2013.
  • Fung MK (ed)., Technical Manual, 18th edition. American Association of Blood Banks, Bethesda, MD, 2014 (or current version).
  • Harmening DM. Modern Blood Banking & Transfusion Practices, 6th edition. F.A. Davis Company, Philadelphia, 2012.
  • Levitt, Judith, chair, Standards of Blood Banks and Transfusion Services, 29th edition. American Association of Blood Banks, Bethesda, MD, 2014 (or current version).
  • Petz Lawrence, Garratty George. Immune Hemolytic Anemias, 2nd edition. Churchill Livingstone, 2004.
  • Reid Marion, Lomas-Francis Olssen Martin. The Blood Antigen Facts Book, 3rd edition. Academic Press, 2012.